Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SONETT: Switch to QD Truvada-based regimen in HIV
NCT00323687Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2004
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Primary endpoint: Proportion of patients with HIV RNA < 400 and with HIV RNA < 50 copies/mL at Week 48. Started Sep 2004; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00323687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00323687.